Coherus BioSciences (CHRS) Misses Q1 EPS by 205c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.60 +2.56%
EPS Growth %: +23.5%
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: +23.5%
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.35), $2.05 worse than the analyst estimate of $1.70. Revenue for the quarter came in at $7.6 million versus the consensus estimate of $54.36 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tradeweb Markets (TW) PT Lowered to $151 at Raymond James
- SpaceX (SPCX) call put ratio 1.2 calls to 1 put as share price down 5.7%
- Fiserv Inc (FISV) call put ratio 2.3 calls to 1 put as share price up 3.5%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
